Citius Oncology, Inc. (CTOR) Cash Flow Statement
Where CTOR’s cash came from and went, FY2025
September 30, 2025 · U.S. dollars- Cash from operations
- −$5.5M −4,446.6% vs FY2024
- Capital expenditures
- $4
- Free cash flow
- −$5.5M
- Returned to shareholders
- —
- Change in cash
- $3.9M cash at year-end $3.9M
Drawn to scale: where the cash came from and how it was used. Hover for values.
CTOR operating cash flow, capex and free cash flow
CTOR cash flow trends, FY2022–FY2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$47,968FY2022 | −$5.5MFY2025 | — | |
| Capital expenditures | $0FY2022 | $4FY2025 | — | |
| Free cash flow | −$47,970FY2022 | −$5.5MFY2025 | — | |
| Operating cash flow / net income | −0.13FY2022 | −0.25FY2023 | −0.12 | |
| Stock-based compensation | $0FY2022 | $8.3MFY2025 | — |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
CTOR cash flow by activity
CTOR net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
CTOR cash flow statement
| FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|
| Operating activities | ||||
| Net income | −$24.8M | −$21.1M | $2.4M | $380,811 |
| Depreciation & amortization | — | — | — | $9.7M |
| Stock-based compensation | $8.3M | $7.5M | $2.0M | $0 |
| Change in working capital | $9.9M | $13.2M | $411,766 | $64,241 |
| Other non-cash items | $1.1M | $576,000 | −$5.4M | −$10.2M |
| Cash from operating activities | −$5.5M | $126,353 | −$601,304 | −$47,968 |
| Investing activities | ||||
| Capital expenditures | −$4 | −$4 | −$4 | $0 |
| Investments (net) | — | −$5.0M | $0 | — |
| Acquisitions & other investing | −$5.7M | $4 | −$1.3M | −$67.3M |
| Cash from investing activities | −$5.8M | −$5.0M | −$1.3M | −$67.3M |
| Financing activities | ||||
| Net borrowing (repayment) | $0 | $3.8M | $0 | — |
| Shares issued | $15.2M | $0 | $0 | $0 |
| Other financing | $0 | $1.1M | $1.7M | $67.7M |
| Cash from financing activities | $15.2M | $4.9M | $1.7M | $67.7M |
| Summary | ||||
| Net change in cash | $3.9M | −$32,633 | −$256,430 | $289,175 |
| Cash at end of period | $3.9M | $112 | $32,745 | $289,175 |
| Free cash flow | −$5.5M | $126,349 | −$601,300 | −$47,970 |
| Operating cash flow / net income | — | — | −0.25 | −0.13 |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$8.9M | −$26.6M | −$5.5M | −$5.0M | −$5.4M | −$7.7M | −$6.7M | −$22.9M | $252,462 | $489,829 | $1.0M | $157,943 |
| Depreciation & amortization | $1.7M | $1.7M | $573,438 | — | $0 | $0 | $0 | — | — | — | — | — |
| Stock-based compensation | $3.6M | $3.5M | $4.0M | $2.3M | $2,125 | $2,088 | $1.8M | $1.7M | $2.0M | $1,957 | $1.9M | $1,966 |
| Change in working capital | $960,975 | $17.9M | −$6.6M | −$3.0M | $3.0M | $5.3M | $4.6M | $13.1M | $17,503 | $76,738 | $28,655 | $297,504 |
| Other non-cash items | −$166,670 | −$503,410 | $264,240 | $142,505 | $2.3M | $2.4M | $264,240 | $9.1M | −$2.6M | −$760,214 | −$3.2M | −$562,938 |
| Cash from operating activities | −$2.8M | −$4.0M | −$7.4M | −$5.5M | $0 | $0 | $0 | $900,288 | −$364,055 | −$191,690 | −$218,190 | −$105,526 |
| Investing activities | ||||||||||||
| Capital expenditures | −$2.0M | −$5 | −$4 | −$5 | $0 | $0 | $0 | −$0 | −$4 | $0 | $0 | −$4 |
| Acquisitions & other investing | −$77,148 | −$660,933 | −$4.4M | −$5.8M | — | — | — | −$29.1M | −$22,544 | $24.7M | −$653,375 | −$640,398 |
| Cash from investing activities | −$2.1M | −$660,938 | −$4.4M | −$5.8M | — | — | — | −$29.1M | −$22,548 | $24.7M | −$653,375 | −$640,402 |
| Financing activities | ||||||||||||
| Shares issued | $0 | $0 | $15.1M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other financing | $19.1M | −$49,672 | $0 | $15.3M | $0 | $0 | $0 | $28.2M | $353,654 | −$24.5M | $875,084 | $411,182 |
| Cash from financing activities | $19.1M | −$49,672 | $15.1M | $15.3M | $0 | $0 | $0 | $28.2M | $353,654 | −$24.5M | $875,084 | $411,182 |
| Summary | ||||||||||||
| Net change in cash | $13.9M | −$4.7M | $3.4M | $3.9M | $0 | $0 | −$32,633 | −$32,633 | −$585 | $585 | $6,222 | −$343,572 |
| Cash at end of period | $16.6M | $2.6M | $7.3M | $3.9M | $112 | $112 | $112 | $112 | $32,745 | $33,330 | $32,745 | $26,523 |
| Free cash flow | −$2.8M | −$4.0M | −$7.4M | −$5.5M | $0 | $0 | $0 | $900,289 | −$364,060 | −$191,690 | −$218,190 | −$105,530 |
| Free cash flow margin | −190.7% | −238.0% | −186.5% | — | — | — | — | — | — | — | — | — |
| Capex / revenue | 133.9% | 0.0% | 0.0% | — | — | — | — | — | — | — | — | — |
| Operating cash flow / net income | — | — | — | — | — | — | — | — | −1.44 | −0.39 | −0.21 | −0.67 |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
CTOR cash generation
In fiscal 2025 (ended September 30, 2025), Citius Oncology generated -$5.5 million of cash from operations (down 4,446.6%) and spent $0.0 million on capital expenditures, leaving free cash flow of -$5.5 million. Cash and equivalents rose by $3.9 million over the year.
Related: CTOR income statement, CTOR balance sheet. See the CTOR stock overview for the latest quote and news.
CTOR cash flow FAQ
What is Citius Oncology's free cash flow?
Citius Oncology's free cash flow was -$5.5 million in fiscal 2025: -$5.5 million of operating cash flow minus $0.0 million of capital expenditures It was $0.1 million a year earlier..
How much cash does Citius Oncology generate from operations?
Citius Oncology generated -$5.5 million of cash from operating activities in fiscal 2025.
How much does Citius Oncology spend on capital expenditures?
Citius Oncology spent $0.0 million on capital expenditures in fiscal 2025, compared with $0.0 million the year before.